Focused On-demand Library for Conserved oligomeric Golgi complex subunit 5

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9UP83

UPID:
COG5_HUMAN

ALTERNATIVE NAMES:
13S Golgi transport complex 90 kDa subunit; Component of oligomeric Golgi complex 5; Golgi transport complex 1

ALTERNATIVE UPACC:
Q9UP83; A4D0R6; A4D0R7; O14555; O95008; Q6NUL5

BACKGROUND:
Conserved oligomeric Golgi complex subunit 5 is essential for Golgi apparatus functionality, implicated in the synthesis and proper folding of glycoproteins. It is identified by several names, including 13S Golgi transport complex 90 kDa subunit and Component of oligomeric Golgi complex 5, reflecting its multifaceted role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Linked to the Congenital disorder of glycosylation 2I, the protein's dysfunction manifests in a wide array of clinical symptoms, from developmental anomalies to immune deficiencies. The exploration of Conserved oligomeric Golgi complex subunit 5's function offers promising avenues for the development of targeted therapies, underscoring its significance in human health and disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 73 of 8789